Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Recro Pharma Inc    REPH

RECRO PHARMA INC

(REPH)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Recro Pharma : in New Supply Agreement with Novartis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 08:58am EST

By Michael Dabaie

Recro Pharma said Monday it entered into a five-year manufacturing and supply agreement with Novartis.

Under the agreement, the company's Recro Gainesville division will continue to be the exclusive global supplier to Novartis of Ritalin LA and Focalin XR capsules through 2023, the company said.

The prior Novartis supply contracts were set to expire in late 2019 and mid-2020, respectively, and provided for two revenue components, product manufacturing revenue and royalty revenue. These agreements were consolidated into the new agreement, which provides for product manufacturing revenue that is expected to provide similar total-revenue-per-capsule economics as the two prior revenue components combined.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS 1.10% 90.08 Delayed Quote.7.19%
RECRO PHARMA INC 1.40% 8.67 Delayed Quote.22.11%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RECRO PHARMA INC
02/14RECRO PHARMA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
02/14Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and..
GL
02/11RECRO PHARMA : in New Supply Agreement with Novartis
DJ
02/11Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between N..
GL
01/07RECRO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/04RECRO PHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sa..
AQ
01/03RECRO PHARMA : Amends Athyrium Credit Facility
AQ
01/02RECRO PHARMA : Amends Athyrium Credit Facility
AQ
2018RECRO PHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sa..
AQ
2018RECRO PHARMA : Amends IV Meloxicam License Agreement with Alkermes
AQ
More news
Financials ($)
Sales 2018 75,5 M
EBIT 2018 -54,3 M
Net income 2018 -54,0 M
Debt 2018 29,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 2,85x
EV / Sales 2019 2,16x
Capitalization 186 M
Chart RECRO PHARMA INC
Duration : Period :
Recro Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECRO PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 14,8 $
Spread / Average Target 71%
EPS Revisions
Managers
NameTitle
Gerri A. Henwood President, Chief Executive Officer & Director
Wayne B. Weisman Chairman
Michael Celano Secretary & Chief Operating Officer
Ryan D. Lake Chief Financial Officer
Stewart Mccallum Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RECRO PHARMA INC22.11%186
GILEAD SCIENCES6.11%87 436
VERTEX PHARMACEUTICALS12.08%48 081
REGENERON PHARMACEUTICALS9.37%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252